JP2012512814A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512814A5
JP2012512814A5 JP2011541029A JP2011541029A JP2012512814A5 JP 2012512814 A5 JP2012512814 A5 JP 2012512814A5 JP 2011541029 A JP2011541029 A JP 2011541029A JP 2011541029 A JP2011541029 A JP 2011541029A JP 2012512814 A5 JP2012512814 A5 JP 2012512814A5
Authority
JP
Japan
Prior art keywords
pain
pharmaceutical composition
composition according
antagonist
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011541029A
Other languages
English (en)
Japanese (ja)
Other versions
JP5674677B2 (ja
JP2012512814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/001671 external-priority patent/WO2010071923A1/en
Publication of JP2012512814A publication Critical patent/JP2012512814A/ja
Publication of JP2012512814A5 publication Critical patent/JP2012512814A5/ja
Application granted granted Critical
Publication of JP5674677B2 publication Critical patent/JP5674677B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011541029A 2008-12-22 2009-12-21 疼痛治療 Active JP5674677B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13968708P 2008-12-22 2008-12-22
US61/139,687 2008-12-22
US16449109P 2009-03-30 2009-03-30
US61/164,491 2009-03-30
PCT/AU2009/001671 WO2010071923A1 (en) 2008-12-22 2009-12-21 Pain treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014138170A Division JP6147704B2 (ja) 2008-12-22 2014-07-04 疼痛治療

Publications (3)

Publication Number Publication Date
JP2012512814A JP2012512814A (ja) 2012-06-07
JP2012512814A5 true JP2012512814A5 (https=) 2013-02-14
JP5674677B2 JP5674677B2 (ja) 2015-02-25

Family

ID=42286785

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011541029A Active JP5674677B2 (ja) 2008-12-22 2009-12-21 疼痛治療
JP2014138170A Active JP6147704B2 (ja) 2008-12-22 2014-07-04 疼痛治療
JP2017074868A Pending JP2017149740A (ja) 2008-12-22 2017-04-05 疼痛治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014138170A Active JP6147704B2 (ja) 2008-12-22 2014-07-04 疼痛治療
JP2017074868A Pending JP2017149740A (ja) 2008-12-22 2017-04-05 疼痛治療

Country Status (12)

Country Link
US (3) US8475796B2 (https=)
EP (2) EP3381471B1 (https=)
JP (3) JP5674677B2 (https=)
KR (1) KR101761324B1 (https=)
CN (2) CN108014335A (https=)
AU (2) AU2009329811B2 (https=)
BR (1) BRPI0918103A2 (https=)
CA (1) CA2747206C (https=)
ES (2) ES2978209T3 (https=)
HK (2) HK1255046A1 (https=)
RU (2) RU2630969C2 (https=)
WO (1) WO2010071923A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
EP3345923A1 (en) * 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
MX2019003019A (es) 2016-09-19 2019-09-19 I Mab Anticuerpos anti-gm-csf y usos de los mismos.
CN120093288B (zh) * 2025-05-08 2025-07-11 中国农业大学烟台研究院 一种牲畜生理行为监测方法及系统

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630496B2 (en) * 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) * 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
EP1442132A2 (en) 2001-10-26 2004-08-04 Novartis AG Methods for the treatment of osteoarthritis and compositions thereof
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040241755A1 (en) 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
CN1960758B (zh) 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
PL1999152T3 (pl) 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008141391A1 (en) 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
PE20091420A1 (es) 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
RU2630969C2 (ru) * 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Similar Documents

Publication Publication Date Title
JP2012512814A5 (https=)
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
JP2009256391A5 (https=)
CY2017039I1 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
JP2011006431A5 (https=)
IL227990B (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
IL215579A (en) Use of 1-benzyl-3-hydroxymethylindazole history to prepare medicinal products for the treatment of diseases based on the expression of 1-mcp, cx3cr1 and 40p
DK2172450T3 (da) Nye malonsyre- og sulfonamidderivater og farmaceutisk brug deraf.
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
HUE038313T2 (hu) Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
FR2941696B1 (fr) Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2962437B1 (fr) Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
RU2016102346A (ru) Лечение боли
LT3135672T (lt) Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
IL225290A0 (en) Cervical pillow for treatment of cervical spine diseases
IL237554B (en) A pharmaceutical preparation containing an antibody against gm-CSF for the treatment of a patient suffering from rheumatoid arthritis
JP2012512815A5 (https=)
HUE042982T2 (hu) Polipeptidek és polinukleotidok, és alkalmazásuk drogcélpontként drogok és biológiai szerek elõállítására